Noxopharm 2026 AGM Chair's Address

Sydney, 17 November 2026: Innovative biotech company **Noxopharm Limited (ASX:NOX)** provides Noxopharm Non-Executive Chairman Mr Frederick Bart's address to the 2026 Annual General Meeting of Shareholders.

-ENDS-

About Noxopharm

Noxopharm Limited (ASX:NOX) is a clinical-stage Australian biotech company discovering and Noxopharm Limited (ASX:NOX) is a clinical-stage Australian biotech company developing novel, targeted therapies for chronic inflammation, autoimmune diseases and cancer.

Noxopharm's proprietary Sofra™ platform is designed to regulate innate immune signalling with greater precision. Its lead clinical asset, SOF-SKN™, is a topical therapy initially being developed for cutaneous lupus erythematosus, with Phase I completed and further clinical development progressing.

Beyond SOF-SKN, the Sofra platform supports a broader pipeline of internal and externally collaborated programs across inflammatory and autoimmune diseases, RNA therapeutics and oncology.

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:
Julian Elliott
M: 0425 840 071
E: julian.elliott@noxopharm.com

Company Secretary:
Shawn van Boheemen
T: +61 414 903 376
E: shawn.vanboheemen@noxopharm.com

Noxopharm CEO Dr Olivier Laczka has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.

Noxopharm 2026 AGM Chair's Address

Fellow Shareholders,

Thank you for taking the time to be here today, and I am pleased to welcome you to Noxopharm's 2026 Annual General Meeting.

We very much appreciate the ongoing support of all our shareholders as we continue to build our company and take it forward.

In particular, we would like to thank everyone who participated in the recent capital raise.

Your support is very welcome as we make progress and further develop a technology platform that we believe has significant potential.

Over the past 12 months the company has met some notable milestones.

One of the most important has been successfully completing a clinical safety trial for SOF-SKN™, our autoimmune drug candidate.

This has opened the way for us to now test the drug on lupus patients, which will happen early next year.

SOF-SKN is a very promising project, especially as there are no specific targeted therapies for this kind of lupus on the market.

But it is not the only achievement this year.

We have also progressed our cancer program, which creates more opportunities for our Sofra platform.

The data we have released over the past few months shows that we have real potential to play a role in a very large global market.

Technologies that harness the immune system against cancer are growing in popularity, and we have a distinct approach that is well protected from an intellectual property point of view.

There is of course still more work to do, but we expect to make even more progress this year with further studies and refinements of our anti-cancer technology.

In general terms, we will look to progress existing external collaborations, and seek new ones from around the world.

Interest in our technology continues to grow, and our credentials have been strengthened by the publication of our core research in *Nature Immunology* earlier this year.

Top global journals such as these receive lots of paper submissions, but only a few make it into print.

That we are one of them reflects how strong our science is, and how far it has come.

In fact, that paper has now been accessed over twenty thousand times by researchers around the world.

It will therefore continue to help us and promote our science as we deepen our collaboration with Professor Gantier and the Hudson Institute team in Melbourne.

In summary, we are well placed for further achievements as we look forward to next year. We have a strong team and great science, plus a clear strategy to develop our platform going forward.

On behalf of the Board, I would like to thank all of our shareholders for your support. It is very much appreciated as we continue to transform Noxopharm and build a successful company.

Thank you.